# Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

> **NCT06121180** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 32 (estimated)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** ZIV-Aflibercept
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT06121180
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2030-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06121180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06121180, "Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06121180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*